Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.69 |
| ▸ | BRAF | P15056 | 6/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.59 |
| ▸ | RET | P07949 | 3/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611716 | 0.89 | KIT (0.73) | KITBRAFABL1EGFRRET | |
| SCHEMBL29562470 | 0.85 | BRAF (0.82) | KITBRAFABL1EGFRRET | |
| SCHEMBL6184307 | 0.85 | BRAF (0.82) | KITBRAFABL1EGFRRET | |
| SCHEMBL5900538 | 0.85 | KIT (0.65) | KITBRAFABL1EGFRRET | |
| SCHEMBL29614753 | 0.83 | KIT (0.65) | KITBRAFABL1EGFRRET | |
| SCHEMBL20227773 | 0.83 | KIT (0.65) | KITBRAFABL1EGFRRET | |
| SCHEMBL4254627 | 0.82 | KIT (0.79) | KITBRAFABL1EGFR | |
| SCHEMBL31053459 | 0.82 | KIT (0.66) | KITBRAFABL1EGFRSRC | |
| SCHEMBL30904911 | 0.82 | KIT (0.71) | KITBRAFABL1EGFRSRC | |
| SCHEMBL20912769 | 0.82 | KIT (0.71) | KITBRAFABL1EGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100427483-C | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | disclosed |
| CN-1720244-A | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2006-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | KIT 3508/4885BRAF 1105/4885ABL1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.